Relationship Between the Uric Acid Level and CNS Relapse Risk in Patients with Newly Diagnosed Adult Diffuse Large B...

Area of Science:

• Hematology
• Oncology
• Immunology

Background:

• Central nervous system (CNS) involvement occurs in 5% of extranodal diffuse large B cell lymphoma (DLBCL) cases at diagnosis.
• The CNS-International Prognostic Index (CNS-IPI) stratifies patients' risk of CNS involvement.
• The correlation between serum uric acid levels and CNS-IPI risk groups or CNS relapse has not been previously studied.

Purpose of the Study:

• To investigate the relationship between serum uric acid levels and the risk of CNS relapse in adult patients with newly diagnosed DLBCL.
• To determine if serum uric acid levels can predict CNS relapse in DLBCL patients.

Main Methods:

• Retrospective analysis of 94 adult DLBCL patients' electronic records and patient files.
• Recorded demographic data, IPI and CNS-IPI scores, and hematologic parameters including serum uric acid levels at diagnosis.
• Compared uric acid levels between CNS-IPI risk groups and analyzed the cumulative incidence of CNS relapses based on uric acid levels.

Main Results:

• Serum uric acid levels were significantly higher in CNS-IPI high-risk patients (p = 0.008).
• Elevated uric acid levels were associated with high CNS-IPI risk (OR 1.34, p = 0.047) and showed discriminatory ability (AUC 0.633, p = 0.05).
• Neither CNS-IPI subgroups nor uric acid levels were significantly associated with the cumulative incidence of CNS relapse in competing risks regression analysis.

Conclusions:

• While serum uric acid levels correlate with CNS-IPI risk stratification, they do not independently predict CNS relapse in DLBCL.
• Elevated uric acid may indicate a higher risk subgroup but lacks predictive power for CNS relapse.
• Further investigation is warranted to elucidate the role of uric acid in DLBCL pathogenesis and CNS involvement.